Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS9531 injection and HRS-5817 injection, agreeing to conduct clinical trials of HRS9531 injection in combination with HRS-5817 injection in adult obese or overweight patients.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS9531 injection and HRS-5817 injection, agreeing to conduct clinical trials of HRS9531 injection in combination with HRS-5817 injection in adult obese or overweight patients.